Galectin Therapeutics Inc.
GALT · NASDAQ
Bulios Fair Price
$3.12
16.4% downside
Current Price
$3.73
According to Bulios Fair Price, GALT is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Galectin Therapeutics Inc. (GALT) is a biopharmaceutical company specializing in the development of therapeutics based on galectin biology for the treatment of fibrotic diseases and cancer. With a portfolio of drug candidates targeting galectin inhibition, key molecules involved in fibrosis and immune regulation processes, Galectin Therapeutics is at the forefront of research and development of therapies for diseases associated with excess connective tissue. The company focuses on utilizing knowledge of galectin biology to discover new drug targets and develop innovative therapeutics with the potential to influence the course of fibrotic diseases and cancer. With growing awareness of the importance of galectins in the pathogenesis of various diseases, Galectin Therapeutics has the potential for further development and research into new therapeutic interventions. Galectin Therapeutics Inc. (GALT) shares could be suitable for investors seeking investment opportunities in the biopharmaceutical industry with an emphasis on innovative therapeutic approaches for fibrotic diseases and cancer.
Sector
Healthcare
Industry
Biotechnology
CEO
Joel Lewis
Employees
9
Headquarters
Norcross
Upcoming events
Earnings
Upcoming earnings report